Who was studied, and how
Three numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 12 other studies
30people with obesity, in this paper
The trial randomly assignedassigned by chance
semaglutide
placebo
Reported lower ad libitum energy intake during lunch, no range given−1255
Reported lower total energy intake across all ad libitum meals throughout the day, no range given−3036
randomisedthe abstract, start to end
… ad libitum energy intake during lunch (-1255 kJ; P < .0001) and during the subsequent evening meal ( P = .0401) and snacks ( P = .0034), resulting in a 24% reduction in total energy intake across all ad libitum meals throughout the day (-3036 kJ; P < .0001).
… from baseline in mean body weight of 5.0 kg, predominantly from body fat …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Ad libitum energy intake during lunchsemaglutide vs placebo
−1255
Total energy intake across all ad libitum meals throughout the daysemaglutide vs placebo
−3036
Mean body weightsemaglutide vs baseline
−5.00
GLP-1 receptor agonistsBody weight & compositionQuality of life & behaviour
GLP-1 receptor agonists × quality of life & behaviourhelps?mixed
unlikelylikely
0.440.50 without it
← favours comparatorfavours treatment →
1 / 7